SCHEMBL24252503

SCHEMBL24252503

Cc1cc2cc(-c3cccc(B(O)O)c3)ccc2c(N)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 1/20 0.67
F12 P00748 1/20 0.67
F11 P03951 1/20 0.67
KLKB1 P03952 1/20 0.67
PRSS1 P07477 1/20 0.67
PRSS2 P07478 1/20 0.67
PRSS3 P35030 1/20 0.67
MGLL Q99685 1/20 0.46
MAP4K4 O95819 3/20 0.42
ENPP2 Q13822 3/20 0.40
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 2/20 0.40
TARS1 P26639 4/20 0.39
DHFR P00374 2/20 0.38
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
DYRK1A Q13627 1/20 0.33
HSD17B1 P14061 1/20 0.33
HSD17B2 P37059 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26771060 0.90 PLG (0.54) PLGF12F11KLKB1PRSS1
Trifluoroacetic Acid SCHEMBL30467710 0.89 PLG (0.55) PLGF12F11KLKB1PRSS1
SCHEMBL24252266 0.78 PLG (0.67) PLGF12F11KLKB1PRSS1
SCHEMBL24252675 0.77 DHFR (0.46) PLGF12F11KLKB1PRSS1
SCHEMBL30451495 0.77 DHFR (0.46) PLGF12F11KLKB1PRSS1
SCHEMBL24252733 0.75 PLG (0.56) PLGF12F11KLKB1PRSS1
SCHEMBL30451657 0.75 PLG (0.56) PLGF12F11KLKB1PRSS1
SCHEMBL12619984 0.71 MGLL (0.86) PLGF12F11KLKB1PRSS1
SCHEMBL30712840 0.71 MGLL (0.86) PLGF12F11KLKB1PRSS1
SCHEMBL31139484 0.71 MGLL (0.86) PLGF12F11KLKB1PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PLG 260/4885F12 29/4885F11 117/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PLG 260/4885F12 29/4885F11 117/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 PLG 260/4885F12 29/4885F11 117/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 PLG 1433/4885F12 38/4885F11 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.